Navigation Links
Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
Date:5/8/2012

ST. LOUIS, May 8, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ:   STXS) today announced that the Company has released to the European market the V-Sono™ intracardiac echocardiography manipulator module for the Vdrive™ Remote Navigation System.

Designed to manipulate accessory devices such as variable loop catheters, steerable sheaths, and ultrasound catheters, the Vdrive™ platform combines magnetic navigation with the Odyssey™ information management system to bring precise control during catheter-based EP procedures.

The Company also announced the first human case using the V-Sono™ module has been performed by Dr. Georg Nolker of Herz und Diabeteszentrum Klinik fur Kardiologie in Bad Oeynhausen, Germany on April 30, 2012.  A patient was treated for a complex left persistent atrial fibrillation and Dr. Nolker performed a fully remote intervention, using the Vdrive Duo™ platform (the V-Loop™ module for the circular mapping catheter and the V-Sono™ module for the ICE catheter) in concert with the Niobe® ES Magnetic Navigation System.

Dr. Nolker said, "Intracardiac Echo has been long established to provide patient safety and cardiac visualization without radiation. This new robotic control makes intracardiac echo more stable, precise, and easier to use in a way that has not been previously available."      

About Stereotaxis           

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey™ portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop™ circular mapping catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.  

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources, including our ability to extend our current loan facility and to obtain additional capital through other financing arrangements, in each case on a timely basis and on terms that are acceptable, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
2. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
3. Stereotaxis Announces Public Offering of Common Stock
4. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
5. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
6. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
7. Stereotaxis System Procedure Featured on NBCs The TODAY Show
8. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
9. Stereotaxis Installs First System in Taiwan
10. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
11. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... CREEK, Calif. , Mar 29, 2017 /PRNewswire/ ... cervical-fusion technology, announced the addition of two industry ... Lynch has joined the company to lead ... assuming International leadership.  Together, Mr. Lynch and Mr. ... experience.  Mr. Lynch joins the ...
(Date:3/29/2017)... March 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical ... non-invasive medical devices for pain management, stroke rehabilitation, cardiac ... host the Company,s 2016 full-year investor webcast on Monday, April ... The Company expects to file its 2016 full ... ...
(Date:3/29/2017)... , March 29, 2017 Optometrists ... patients as the highest standard in quality and ... Vision introduces its objective Wavefront-driven refraction technologies and ... approach. This enables an unprecedented level of refraction ... exceptional vision relegated to Topgun Navy fighter pilots, ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... March 30, 2017 , ... Although many people are wary of baring ... wary of baring their skin for other reasons, including unsightly skin conditions like dermatitis, ... get the skin prepared for the summer weather and allow individuals to hit the ...
(Date:3/30/2017)... ... ... manicurist from Greet, S.C., wants to offer people a new way to care for their ... feet, so I know the importance of proper foot care," he said. "In order to ... , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms of his ...
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has named ... more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers a ... cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box blades. ...
(Date:3/29/2017)... ... , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S ... serve as the official title sponsor of the Baltimore Women’s Classic, the largest all ... women will walk or run the course around the Baltimore Inner Harbor. Mercy has ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 ... Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while ... HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, Lower ...
Breaking Medicine News(10 mins):